Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lifu Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5172-9932; OpenAlex author ID A5101922066. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 10

  1. Isoleucyl-tRNA synthetase 2 promotes pancreatic ductal adenocarcinoma proliferation and metastasis by stabilizing β-catenin. Last author DOI 10.1016/j.gendis.2024.101382↗
  2. Targeting MTPN sensitizes pancreatic cancer of wild-type BRCA1/2 to Cisplatin-based chemotherapy. Last author DOI 10.1038/s41417-025-00925-5↗
  3. IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer. Co-author DOI 10.1007/s00262-024-03669-7↗
  4. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2022.827051↗
  5. SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells. Last author DOI 10.1111/cpr.12799↗
  6. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway. Last author DOI 10.3892/ol.2020.12009↗
  7. Cigarette Smoking and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1097/mpa.0000000000001383↗
  8. EI24 Suppresses Tumorigenesis in Pancreatic Cancer via Regulating c-Myc. Last author DOI 10.1155/2018/2626545↗
  9. Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer. Last author DOI 10.18632/oncotarget.7158↗
  10. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000271↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhuoxin Wang · 4 shared papers, 2022–2025 · strength 0.98
  2. Xinyang Huang · 4 shared papers, 2020–2025 · strength 0.83
  3. Yixun Jin · 3 shared papers, 2022–2025 · strength 0.72
  4. Qi Wang · 4 shared papers, 2016–2025 · strength 0.62
  5. Tingting Gong · 2 shared papers, 2024–2025 · strength 0.51
  6. Qi Wang · 2 shared papers, 2020–2024 · strength 0.37
  7. Qi Wang · 1 shared paper, 2025 · strength 0.26
  8. Yi Zang · 3 shared papers, 2016–2020 · strength 0.23
  9. Tong Li · 2 shared papers, 2020 · strength 0.21
  10. Xu Liu · 2 shared papers, 2020 · strength 0.21
  11. Qiwen Ben · 2 shared papers, 2015–2019 · strength 0.17
  12. Yaozong Yuan · 2 shared papers, 2015–2019 · strength 0.17
  13. Liangchao Zhao · 1 shared paper, 2022 · strength 0.16
  14. Hui Xu · 1 shared paper, 2022 · strength 0.16
  15. Tong Li · 1 shared paper, 2022 · strength 0.16
  16. Yunwei Sun · 1 shared paper, 2019 · strength 0.11
  17. Duowu Zou · 1 shared paper, 2019 · strength 0.11
  18. Lei Zhu · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.